Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review

Ian Pearce MBChB1 | Rafael Simó MD2 | Monica Lövestam-Adrian MD3 | David T. Wong MD4 | Marc Evans MD5

1St Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, UK
2Vall d’Hebron Research Institute (VHIR) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain
3Lund University Hospital, Lund, Sweden
4St. Michael’s Hospital, University of Toronto, Toronto, Canada
5University Hospital Llandough, Llandough, Wales, UK

Correspondence
Marc Evans, University Hospital Llandough, Penlan Road, Llandough CF64 2XX, Wales, UK.
Email: marclyndon1@hotmail.com

Funding information
Support for this project was provided by the Vision Academy, a Bayer-sponsored initiative comprising over 70 leading retinal specialists.

The aim of this systematic review was to examine the associations between diabetic retinopathy (DR) and the common micro- and macrovascular complications of diabetes mellitus, and how these could potentially affect clinical practice. A structured search of the PubMed database identified studies of patients with diabetes that assessed the presence or development of DR in conjunction with other vascular complications of diabetes. From 70 included studies, we found that DR is consistently associated with other complications of diabetes, with the severity of DR linked to a higher risk of the presence of, or of developing, other micro- and macrovascular complications. In particular, DR increases the likelihood of having or developing nephropathy and is also a strong predictor of stroke and cardiovascular disease, and progression of DR significantly increases this risk. Proliferative DR is a strong risk factor for peripheral arterial disease, which carries a risk of lower extremity ulceration and amputation. Additionally, our findings suggest that a patient with DR has an overall worse prognosis than a patient without DR. In conclusion, this analysis highlights the need for a coordinated and collaborative approach to patient management. Given the widespread use of DR screening programmes that can be performed outside of an ophthalmology office, and the overall cost-effectiveness of DR screening, the presence and severity of DR can be a means of identifying patients at increased risk for micro- and macrovascular complications, enabling earlier detection, referral and intervention with the aim of reducing morbidity and mortality among patients with diabetes. Healthcare professionals involved in the management of diabetes should encourage regular DR screening.

KEYWORDS
diabetes complications, diabetic retinopathy

1 INTRODUCTION

Diabetic retinopathy (DR) is the most common complication of diabetes and remains the leading cause of blindness among working-age individuals in most developed countries.1,2 DR has long been considered a microvascular complication of diabetes; however, growing evidence suggests that abnormalities in retinal function can be detected in patients without any evidence of microvascular abnormalities, and the American Diabetes Association defined DR as a highly specific neurovascular complication.3,4

DR is characterized by degeneration of endothelial cells and pericytes in retinal capillaries, which leads to ischaemia and the formation of microaneurysms.5 In the advanced stage of the disease, pathologic proliferation of retinal vessels occurs via upregulation of proangiogenic mediators, particularly vascular endothelial growth factor (VEGF).5 The resulting alterations of the retinal microvasculature and increased leakage from the retinal vessels may lead to sight-threatening vision loss.5

As the number of adults with diabetes worldwide is projected to increase from 415 million to 642 million by 2040,6 DR represents a significant global health threat. According to recent estimates, DR
accounts for 2.6 million cases of moderate to severe vision impairment worldwide, and this figure is expected to rise to 3.2 million by 2020.

A pooled analysis of data from 35 studies conducted in the United States, Europe, Asia and Australia estimated that in 2010, worldwide, the number of patients with diabetes who had DR or vision-threatening DR (VTDR) was 92.6 and 28.4 million, corresponding to prevalence rates of 34.6% and 10.2%, respectively. The global number of patients with diabetes who have retinopathy in the general population is projected to reach 191 million by 2030.

Longer duration of diabetes is a major risk factor for DR. One study estimated that individuals who have type 1 diabetes mellitus (T1DM) for 20 years or more are 2.7 times more likely to develop retinopathy (relative risk [RR], 2.69; 96% confidence interval [CI], 2.47-2.93), and are 8.7 times more likely to have VTDR (RR, 8.69; 96% CI, 7.10-10.63), compared with individuals who have type 2 diabetes mellitus (T2DM) for less than 10 years. However, more recently, DR has also been reported with various prevalence rates in patients with newly diagnosed diabetes mellitus.

Treatment of DR significantly improved after the introduction of pharmacological agents with anti-VEGF activity. In phase III clinical trials of patients with diabetic macular oedema (DMO), a complication of DR, anti-VEGF therapy improved visual acuity from baseline and lowered the risk of progression to proliferative DR (PDR), indicating that VEGF inhibitors can interfere with the underlying pathogenesis of retinopathy. However, delayed DR screening and detection can hamper treatment. In one UK study, there was a significant trend (P = 0.0004) relating time from diagnosis of T2DM to detection of worsening retinopathy at screening.

The consequences of delayed detection of DR extend beyond suboptimal visual acuity outcomes; increasing evidence links retinopathy to other microvascular complications of diabetes, most notably nephropathy and cardiac autonomic neuropathy (CAN). Retinopathy has also been linked to macrovascular comorbidities, including stroke, myocardial infarction and, potentially, heart failure. Additionally, a recent meta-analysis of epidemiological observational studies found that patients with diabetes who have DR are at increased risk of all-cause mortality, compared with patients with diabetes who do not have retinopathy (risk ratio [RR], 2.33; 95% CI, 1.92-2.81). With regard to the link between DR and cardiovascular events, Alonso et al. conducted a cross-sectional study of patients with T2DM who did not have renal deficits or prior history of cardiovascular disease (CVD). They found that the percentage of patients with carotid plaques, a risk factor for ischaemic stroke, was higher among those with DR than among those without DR (68.0% vs 52.2%; P = 0.0045). Other research has demonstrated that, not only is DR associated with future cardiovascular events, but also that the risk of these events increases with increasing severity of DR (hazard ratio [HR], 1.49; 95% CI, 1.12-1.97 for mild retinopathy and HR, 2.35; 95% CI, 1.47-3.76 for severe retinopathy). Similar associations have been observed between DR and cerebrovascular events.

Our analysis aimed to further elucidate the relationships between DR and micro- and macrovascular complications, and to identify any examples where the presence of DR increases the risk of having or developing other complications of diabetes. Irrespective of the directionality of any such relationships, that is, whether DR is antecedent to or develops after other complications, an increased awareness and understanding of these relationships can help promote timely referral and discussion between ophthalmologists and the other healthcare professionals involved in the management of these co-morbidities, including diabetologists, cardiologists, vascular surgeons and nephrologists. There is currently a lack of communication between the diverse healthcare disciplines involved in the treatment of patients with diabetes, which can lead to a breakdown in the care pathway and contributes to suboptimal patient outcomes. DR screening can be performed effectively outside the ophthalmologist's office by trained personnel (eg, primary care physician's office, optometrist, mobile unit). Indeed, this approach is generally deemed more practical and efficient than screening at ophthalmology offices. The identification of patients with DR and a greater understanding of the wider relevance of DR may provide an opportunity to identify patients who are at increased risk of the presence or development of other diabetic complications, thus forming the basis for enhanced inter-disciplinary communication with the aim of improving patient outcomes.

## 2 MATERIALS AND METHODS

### 2.1 Research questions

The aim of this study was to answer the following research questions:

- Is there a link between DR and the micro- and macrovascular complications of diabetes?
- Does DR increase the risk of other complications of diabetes?
- What is the clinical significance of the associations between DR and other complications of diabetes?

### 2.2 Literature search strategy

A literature search of the PubMed database was performed using a structured approach to identify relevant studies. The search term combination used was: ((((((diabetes) OR diabetic) OR diabetes mellitus) AND (((((retinopathy) OR eye disease) OR macular disease))) AND (((((intermittent claudication) OR vasculopathy) OR peripheral artery disease) OR cerebrovascular event) OR cerebral ischemia) OR cerebrovascular disease) OR stroke) OR cerebrovascular event) OR transient ischemic attack) OR (((((coronary heart disease) OR myocardial ischemia) OR cardiovasculosis))) OR (((((coronary heart disease) OR myocardial ischemia) OR cardiovasculosis))) OR (((((cerebrovascular accident) OR cerebral infarction) OR cerebral ischemia) OR cerebral disease) OR stroke) OR cerebrovascular event) OR transient ischemic attack) OR (((((intermittent claudication) OR vasculopathy) OR peripheral artery disease) OR ulcer) OR gangrene) OR peripheral vascular disease) OR necrosis) OR amputation))) AND (((((risk) OR risk factor) OR association) OR correlation) OR logistic regression) OR predictive) OR predictor) OR predictive factor) OR link) OR relationship)).

Diabetes search terms were restricted to title content, and the remaining search terms were limited to title and abstract. Only peer-reviewed original research studies and reviews were included, and no geographical, date or language restrictions were applied.
Inclusion criteria were: (a) studies involving a population of patients with diabetes, with no restriction on clinical characteristics, glycated haemoglobin (HbA1c) and comorbidity or treatment history, and (b) studies that evaluated the presence or development of DR in conjunction with other vascular complications of diabetes.

Data extraction

For the first stage of the selection process, identified titles were screened for relevance. If the publication passed this stage, the abstract was read to verify relevance, and if this was confirmed, the full text of the paper was assessed against the inclusion and exclusion criteria. Extracted information included study design, population characteristics, conclusions and limitations. Precedence was given to studies specifically designed to investigate the relationship between DR and other complications of diabetes, and to studies in which statistical analyses were adjusted for confounding factors.

RESULTS

Study selection

Of 3028 potentially relevant papers initially identified through the PubMed search, 2418 were excluded because they were not relevant to the research questions. The abstracts of the remaining 610 papers were read, which led to the exclusion of an additional 330 papers. This resulted in a total of 280 papers of which the full text was assessed for relevance. Of these papers, 71 met the criteria for inclusion in the structured review.

DR and other microvascular complications of diabetes

A correlation was found between DR and other microvascular complications of diabetes, specifically, nephropathy and neuropathy. A summary of the findings of the reviewed studies that examined the

TABLE 1

| Reference | Study population | Study design (n) | Independent variable | Dependent variable | OR/HR/RR (95% CI) | P value |
|-----------|------------------|-----------------|----------------------|-------------------|-------------------|---------|
| El-Asrar14 | T1DM & T2DM     | Cross-sectional (648) | DR                  | Nephropathy       | All: OR = 4.37 (2.19-8.71) | <0.05   |
|           |                  |                  |                     |                   | T1DM: OR = 8.02 (1.95-33) | <0.05   |
|           |                  |                  |                     |                   | T2DM: OR = 2.48 (1.02-6.03) | <0.05   |
|           |                  |                  |                     |                   | OR = 3.78 (1.86-7.67) | <0.05   |
|           |                  |                  |                     |                   | OR = 7.17 (2.43-20.61) | <0.05   |
|           |                  |                  |                     |                   | OR = 23.56 (8.49-66.11) | <0.05   |
| P. Rossing15 | T1DM          | Prospective (537) | DR                  | Progression to microalbuminuria/macroalbuminuria | RR = 1.90 (1.26-2.88) | <0.01   |
| Parving25 | T2DM             | Cross-sectional (32208) | DR                  | Microalbuminuria/macroalbuminuria | OR = 1.49 (1.38-1.62) | <0.0001 |
| Karlberg26 | T1DM             | Prospective (184) | PDR                 | Nephropathy       | OR = 2.98 (1.18-7.51) | 0.02    |
| Kramer 201327 | T1DM         | Retrospective (1365) | DR progression | Nephropathy development | HR = 1.72 (1.30-2.27) | <0.001  |
| Romero-Aroca 201228 | T1DM | Prospective (110) | DR                  | Overt nephropathy | OR = 3.92 (2.97-7.69) | 0.030   |
| Romero-Aroca 201129 | T1DM | Prospective (334) | Overt nephropathy | DMO | HR = 0.68 (0.51-0.90) | 0.008   |
| Hammes 201530 | T2DM         | Longitudinal (64784) | Microalbuminuria | DR | OR = 1.16 (1.11-1.20) | <0.0001 |
|           |                  |                  | Macroalbuminuria | Severe DR | OR = 1.20 (1.14-1.27) | <0.0001 |
|           |                  |                  |                     | DMO | OR = 1.31 (1.09-1.58) | <0.0001 |
|           |                  |                  |                     | DR | OR = 1.28 (1.12-1.39) | <0.0001 |
|           |                  |                  |                     | Severe DR | OR = 1.51 (1.36-1.67) | <0.0001 |
|           |                  |                  |                     | DMO | OR = 2.77 (2.11-3.66) | <0.0001 |
| Jeng31 | T1DM & T2DM     | Longitudinal (53453) | Nephropathy | NPDR | HR = 5.01 (4.68-5.37) | <0.001  |
|           |                  |                  |                     | PDR | HR = 9.70 (8.15-11.50) | <0.001  |
|           |                  |                  |                     | Progression from NPDR to PDR | HR = 2.25 (1.66-3.02) | <0.001  |
| Savage32 | T2DM             | Cross-sectional (947) | Macroalbuminuria | Increasing severity of DR | OR = 2.89 (1.73-4.61) | 0.0001  |
| Takagi33 | T2DM             | Prospective (1802) | DR                  | Microalbuminuria | OR = 1.57 (1.17-2.12) | <0.003  |
|           |                  |                  |                     | Decrease in eGFR | OR = 1.36 (1.08-1.71) | 0.008   |
| Moriya34 | T2DM             | Retrospective (1475) | DR + microalbuminuria | Macroalbuminuria | HR = 11.55 (5.24-25.45) | <0.01   |

Abbreviations: CI, confidence interval; DMO, diabetic macular oedema; DR, diabetic retinopathy; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NPDR, non-proliferative diabetic retinopathy; OR, odds ratio; PDR, proliferative diabetic retinopathy; RR, relative risk; STD, sight-threatening diabetic retinopathy; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
relationship between DR and these microvascular complications is presented in Tables 1 and 2.

### 3.2.1 Nephropathy

Diabetic nephropathy affects approximately 40% of patients with diabetes and is characterized by increased urinary albumin excretion (UAE). It is categorized into stages, microalbuminuria (UAE >20 µg/min and ≤199 µg/min) and macroalbuminuria (UAE ≥200 µg/min), and it is associated with increased mortality. Glomerular filtration rate (GFR), a measure of renal function, is also used to assess the presence of diabetic nephropathy. Overall, risk estimates from the reviewed studies suggest a correlation between DR and nephropathy, and between DR and declining renal function (Table 1).

**DR and albuminuria**

In a cross-sectional study of patients with T1DM or T2DM, the presence and severity of DR were significantly predictive of nephropathy. Multivariate logistic regression showed that nephropathy was the only complication of diabetes independently associated with DR, and that retinopathy increased the likelihood of developing nephropathy by 4.37 times. However, the predictive value of DR was the only complication of diabetes independently associated with nephropathy. These findings have been confirmed in other studies that identified DR as a significant independent predictor of progression from micro- or macroalbuminuria in patients with T1DM or T2DM. Risk of nephropathy has been shown to increase with DR severity, and PDR was identified as a significant independent marker of incident nephropathy in a 25-year follow-up study in T1DM.

### TABLE 2 Studies describing the association between DR and diabetic neuropathy

| Reference Study population | Study design (n) | Independent variable | Dependent variable | OR/HR (95% CI) | P value |
|----------------------------|-----------------|----------------------|-------------------|----------------|---------|
| Kostev38 T2DM              | Retrospective (45633 [German cohort only]) | DR                   | Neuropathy        | OR = 2.96 (2.08-4.22) | <0.05   |
| Jurado39 T2DM              | Cross-sectional (307) | DR                   | DPN               | OR = 5.18 (2.70-10.00) | 0.000   |
| Abougalambou40 T2DM       | Prospective (1077) | Neuropathy           | DR                | OR = 2.91 (2.21-3.82) | <0.001  |
| Lin41 DPN                  | Retrospective (5031 [+20 124 controls]) | DPN                  | Any DR            | HR = 5.41 (4.92-5.94) | <0.001  |
| Zander42 T1DM & T2DM       | Cross-sectional (33659) | Neuropathy           | Maculopathy       | T1DM: OR = 3.5 (NR)  | <0.01   |
| Witte43 T1DM               | Prospective (956) | DR                   | CAN               | OR = 1.70 (1.11-2.60) | 0.01    |
| Ko44 T2DM                  | Prospective (1021) | DR                   | CAN               | OR = 1.51 (1.03-2.23) | 0.036   |
| Voulgari45 T1DM & T2DM     | Cross-sectional (600) | DR                   | CAN               | T1DM: OR = 1.13 (1.04-1.41) | 0.01    |
| Huang46 T2DM               | Cross-sectional (174) | NPDR                 | PDR               | OR = 2.73 (1.14-6.54) | 0.024   |
| H. T. Chen46 T2DM          | Cross-sectional (674) | PDR                  | CAN               | OR = 11.19 (4.15-30.16) | <0.001  |
| Gaspar47 T1DM & T2DM       | Retrospective (187) | DR                   | Orthostatic hypertension | T1DM: OR = 8.09 (1.65-39.62) | <0.01   |

Abbreviations: CAN, cardiac autonomic neuropathy; CI, confidence interval; DPN, diabetic peripheral neuropathy; DR, diabetic retinopathy; HR, hazard ratio; NPDR, non-proliferative diabetic retinopathy; NR, not reported; OR, odds ratio; PDR, proliferative diabetic retinopathy; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

Interestingly, data from the Diabetes Control and Complications Trial (DCCT) in T1DM demonstrated that progression of DR independently increases the risk of development of nephropathy, and also showed that the development of nephropathy increases the risk of DR progression. Although a previous study demonstrated that these two complications influence the incidence of each other, a retrospective study in T2DM demonstrated that the association between DR and diabetic nephropathy is unidirectional and that renal injury precedes retinal damage. Accordingly, several studies have shown that nephropathy is a risk factor for DR, including severe forms of retinopathy. Concerning T1DM, a 20-year prospective study by Romero-Arca et al. found that both micro- and macroalbuminuria correlated with the development of VTDR but not with the development of any DR. In the same study, DR was a significant risk factor for nephropathy. Notably, in a 10-year prospective analysis of patients with T1DM, macroalbuminuria was identified as a significant independent risk factor for the development of DMO, but not of DR. Concerning T2DM, Hammes et al. analysed data from 6478 patients. The presence of microalbuminuria was found to independently increase the risk of DR, severe DR and DMO, and the risk further increased in the presence of macroalbuminuria. However, research has also shown that nephropathy did not affect development or progression of DMO, although it was an independent risk factor for DR, PDR and the progression from non-proliferative DR (NPDR) to PDR. Previously, macroalbuminuria, but not microalbuminuria, had been found to be significantly associated with increasing severity of DR and with progression from NPDR to PDR in T2DM.
Dr and Declining Renal Function
In a single-centre observational cohort study by Takagi et al., the presence of DR was a common predictor of both albuminuria onset and decreased estimated GFR (eGFR) in patients with T2DM. In earlier research, also involving patients with T2DM, Rosling et al. found a significant correlation between degree and presence of DR at baseline and increased rate of eGFR decline. Interestingly, in the Japan Diabetes Complications Study, patients with T2DM who had both microalbuminuria and DR at baseline had the highest risk of developing macroalbuminuria and displayed significantly faster eGFR decline (−1.92 mL min⁻¹ 1.73 m⁻² year⁻¹; P < 0.01) compared with those with one of the two complications (−0.69 mL min⁻¹ 1.73 m⁻² year⁻¹; P < 0.01) or with neither complication (−0.54 mL min⁻¹ 1.73 m⁻² year⁻¹; P < 0.01).

3.2.2 | Neuropathy
DR was found to be associated with two neuropathies: diabetic peripheral neuropathy (DPN) and CAN (Table 2). DPN is estimated to affect 30% to 50% of individuals with diabetes; it is characterized by peripheral nerve injury and manifests most commonly as distal symmetric polyneuropathy (DSP). Symptoms of DSP include pain, numbness and weakness in the lower limbs, which may lead to falls. Diabetic symmetric polyneuropathy is also a major risk factor for foot ulcers and amputations. Concerning CAN, reported prevalence rates among individuals with diabetes vary from 17% to 66% in T1DM, and from 31% to 73% in T2DM. Nerve injury occurs in both the autonomic and peripheral nervous systems, increasing the likelihood of experiencing heart rate abnormalities that progress to resting tachycardia, as well as orthostatic hypotension, ischaemia, CVD, chronic kidney disease and anaemia. Additionally, individuals with diabetes who have CAN are at increased risk of mortality compared with those without.

Dr and DPN/DSP
In a retrospective study of longitudinal data from patients with newly diagnosed T2DM, collected from nationwide general practitioners in Germany and the UK, the presence of microvascular complications, defined as DR plus nephropathy, was found to be independently associated with neuropathy; in particular, DR was identified as a significant risk factor for neuropathy in the German cohort. Furthermore, the longitudinal Rochester Diabetic Neuropathy Study demonstrated that DR severity was an independent risk factor for DPN severity in patients with T1DM. A positive correlation between DPN and DR was also found in the cross-sectional North Catalonia Diabetes Study, in which the presence of retinopathy, together with age, HbA1c and plasma levels of high-density lipoprotein cholesterol, was used in a model to evaluate the risk of DPN. Based on these four parameters selected by logistic regression analysis, the sensitivity and specificity of the model for diagnosis of DPN was 74.2% and 74.9%, respectively.

Other studies, including a prospective analysis of patients with T2DM in Malaysia, showing that neuropathy is an independent risk factor for progression of retinopathy, found neuropathy to be a predictor of DR onset and progression. Similarly, in a retrospective population-based study in Taiwan, patients with DPN exhibited an increased risk of DR and advanced DR compared with a matched cohort of patients with diabetes who did not have DPN. Notably, when stratified according to DR severity, the risk of DPN was greater in patients with PDR than in those with NPDR. A significant association has also been found between diabetic maculopathy and neuropathy in both patients with T1DM and patients with T2DM, taking into account both peripheral neuropathy and CAN.

Dr and CAN
In the EURODIAB Prospective Complications Study, Witte et al. investigated potential risk factors for CAN in patients with T1DM. They found that the presence of DR or PDR at baseline was significantly associated with CAN incidence (P < 0.05) after controlling for sex, diabetes duration and HbA1c. 17% of 956 patients developed the complication over the 7.3 years of follow-up, corresponding to an incidence rate of 23.4 per 1000 person-years. The association remained significant after multivariate regression analyses. A similar conclusion was drawn from a seven-year follow-up study of patients with T2DM who had normal cardiac autonomic function at baseline. Logistic regression revealed that the presence of DR was predictive of CAN progression after adjusting for age, hypertension, smoking and diabetes duration.

Overall, the above findings are consistent with those of a cross-sectional study by Voulgari et al. indicating that the odds of CAN are independently increased by the presence of DR in both T1DM and T2DM patient populations, and with the results of a study of patients with T2DM showing that increasing DR severity is associated with a higher risk of developing CAN. A significant positive correlation between DR severity and risk of CAN in patients with T2DM was also reported by Chen et al. after adjusting for age, sex, diabetes duration and HbA1c. Additionally, after logistic regression analysis, the authors identified PDR as the most significant single risk factor for CAN.

Of note are the results of a 10-year follow-up study that found DR to be significantly more prevalent in individuals with diabetes who have orthostatic hypertension, a major clinical feature of CAN, compared with individuals without.

3.3 | Dr and Macrovascular Complications of Diabetes
In addition to the microvascular complications described above, the presence of DR has also been associated with development of the macrovascular complications of diabetes, specifically, cerebrovascular complications (stroke, cerebral infarction/haemorrhage), cardiovascular complications (atherosclerosis, cardiovascular events, coronary heart disease [CHD]) and peripheral complications (foot ulcers, lower extremity amputations, peripheral arterial disease [PAD]). The key findings of the reviewed studies examining the relationship between DR and various types of macrovascular complications of diabetes are presented in Tables 3–5.
TABLE 3  Studies describing the association between DR and cerebrovascular complications

| Reference  | Study population | Study design (n) | Independent variable | Dependent variable | OR/HR/RR (95% CI) | P value |
|------------|------------------|-----------------|----------------------|--------------------|------------------|---------|
| Petitti52   | T1DM & T2DM      | Case-control (2124) | DR | Ischaemic stroke | RR = 4.0 (1.0-14.5) | <0.05  |
| Cheung 200753 | T1DM & T2DM   | Prospective (1617) | DR | Ischaemic stroke | HR = 2.34 (1.13-4.86) | <0.05  |
| B. E. Klein54 | T1DM          | Prospective (996) | DR/step  | Stroke | OR = 1.6 (11.2-3) | 0.01   |
| Hägg 201322 | T1DM            | Observational follow-up (4803) | Severe DR | Stroke/Cerebral infarction/Cerebral haemorrhage | HR = 3.0 (1.9-4.5) HR = 2.7 (1.6-4.4) HR = 3.9 (1.7-8.9) | <0.05  |
| Hägg 201421 | T1DM            | Observational follow-up (4803) | Severe DR | Haemorrhagic stroke | HR = 2.99 (1.18-7.55) | 0.021  |
| Kawasaki 201355 | T2DM       | Prospective (2033) | Mild to moderate DR | Stroke | HR = 1.69 (1.03-2.80) | 0.04   |
| Hankey23    | T2DM            | Prospective, observational (9795) | History of DR | Small-artery ischaemic stroke | HR = 1.82 (1.08-3.07) | 0.03   |
| Cheung 201056 | T1DM & T2DM   | Prospective (810) | DR | Incident cerebral infarct/Incident lacunar infarct | OR = 7.25 (1.72-31.34) OR = 5.32 (1.23-23.03) | NR     |
| Lip57       | T1DM & T2DM     | Registry (8962) | DR | Stroke/thromboembolism | RR = 1.21 (0.80-1.84) | 0.37   |
| Chou58      | T1DM & T2DM     | Registry (50180) | DR | Ischaemic stroke | HR = 1.11 (0.95-1.30) | 0.204  |

Abbreviations: CI, confidence interval; DR, diabetic retinopathy; HR, hazard ratio; NR, not reported; OR, odds ratio; RR, relative risk; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

3.3.1 | Cerebrovascular complications

An early case-control study identified DR as a risk factor for non-embolic ischaemic stroke in individuals with diabetes, independent of smoking, blood pressure and other complications of diabetes.52 The findings were later supported by a population-based, prospective study of patients with diabetes that found DR to be significantly correlated with incident stroke, although no association was identified between DR grade and increasing risk of ischaemic stroke.53 This differs from the results of the Wisconsin Epidemiologic Study of Diabetic Retinopathy in T1DM, which demonstrated an association between DR severity and increased odds of stroke.54 Similarly, in the Finnish Diabetic Nephropathy (FinnDiane) Study, severe DR independently increased the risk of stroke, cerebral infarction and cerebral haemorrhage in patients with T1DM who were followed for 9 years, and the risk increased if patients had concomitant diabetic nephropathy.22 Further analysis of this data set revealed severe DR to be independently associated with haemorrhagic stroke but not with ischaemic stroke,21 whereas a large prospective study in patients with T2DM who were followed for 5 years found DR to be correlated with small-artery ischaemic stroke, but not with large-artery ischaemic stroke or haemorrhagic stroke.23 An analysis of data from the Japan Diabetes Complications Study revealed that even patients with mild to moderate NPDRI had an increased risk of stroke after adjusting for traditional cardiovascular risk factors.55 Furthermore, in the Atherosclerosis Risk in Communities (ARIC) Brain MRI Study, DR was associated with the emergence of subclinical brain infarcts.56

3.3.2 | Cardiovascular complications

Increased carotid intima-media thickness (cIMT) is a broadly accepted marker for early or subclinical atherosclerosis,59 and several studies have demonstrated an association between DR and this marker.17,60–65 In a cross-sectional analysis of patients with T2DM, DR severity was associated with elevated cIMT after controlling for other risk variables.60 These findings are consistent with those from the Chennai Urban Rural Epidemiology Study (CURES-2)61 and several other cross-sectional investigations.62–64 Furthermore, Li et al. found the presence of retinal microvascular abnormalities, defined as DR or retinal arteriosclerosis, to be independently associated with increased cIMT in both men and women with T2DM, and with increased carotid plaque presence in men with T2DM.66 In research by de Kreutzenberg et al. DR alone, or co-existing with nephropathy, was significantly and independently associated with carotid plaque presence in patients with T2DM,67 and Alonso et al. showed DR to be independently correlated with cIMT, carotid artery plaque presence and carotid burden in patients with T2DM.17

Contrary to the evidence described above, DR presence was not associated with increased cIMT in a cross-sectional study that examined the relationship between DR severity and risk factors for subclinical CVD in a cohort of individuals with diabetes who had no history of clinical CVD.68 However, the study found that severe retinopathy doubled the odds of a high coronary artery calcium (CAC) score and a low ankle-brachial index (ABI) after adjusting for cardiovascular risk factors, HbA1c, nephropathy and diabetes duration.68 A correlation between PDR and high CAC scores was also identified in the Veterans Affairs Diabetes Trial (VADT). Through logistic regression analysis, PDR presence in patients with T2DM was estimated to increase the likelihood of a CAC score greater than 400 by six times, compared with no PDR presence.59 It is worth noting, however, that, in a prospective study of individuals with T2DM who were followed for up to 8 years, even mild to moderate DR increased the risk of CHD and stroke.55 In addition, in a case-controlled study, the odds ratio of myocardial perfusion defects in an asymptomatic patient who
| Reference          | Study population | Study design (n) | Independent variable | Dependent variable | OR/HR/RR/β (95% CI) | P value |
|--------------------|------------------|------------------|----------------------|--------------------|---------------------|---------|
| R. Klein           | T2DM             | Cross-sectional  | cIMT                 | DR                 | OR = 1.09 (1.01-1.17) | 0.02    |
| Rema               | T2DM             | Cross-sectional  | cIMT                 | DR                 | OR = 3.60 (1.51-8.46) | 0.004   |
| Liu                | T2DM             | Cross-sectional  | cIMT                 | DR                 | OR = 1.84 (1.02-3.31) | 0.043   |
| Saif               | T2DM             | Cross-sectional  | cIMT                 | DR                 | NR                  | <0.0001 |
| Son                | T2DM             | Cross-sectional  | cIMT                 | DR                 | OR = 6.57 (1.68-25.71)| 0.007   |
| L. X. Li           | T2DM             | Cross-sectional  | DR                   | cIMT               | All: β = 0.078 (0.080-0.262) | <0.001 |
|                   |                  |                  |                      |                    | Men: β = 0.067 (0.026-0.269) | 0.018   |
|                   |                  |                  |                      |                    | Women: β = 0.087 (0.058-0.334) | 0.005   |
|                   |                  |                  |                      |                    | All: OR = 1.72 (1.32-2.24) | <0.001  |
|                   |                  |                  |                      |                    | Men: OR = 2.17 (1.54-3.05) | <0.001  |
| de Kreutzenberg    | T2DM             | Cross-sectional  | DR                   | Carotid plaques    | OR = 3.44 (1.71-7.57) | 0.0011  |
| Alonso             | T2DM             | Cross-sectional  | DR                   | ICA-IMT            | OR = 1.71 (1.03-2.85) | 0.017   |
| Kawasaki 2011      | T1DM & T2DM      | Cross-sectional  | VTDR                 | CAC                | OR = 2.33 (1.15-4.73) | <0.05   |
| Kawasaki 2013      | T2DM             | Prospective      | Mild NPDR            | CHD                | HR = 1.62 (1.02-2.58) | 0.04    |
|                   |                  | (2033)           | Mild to moderate NPDR| CHD                | HR = 1.69 (1.09-2.63) | 0.02    |
|                   |                  |                  |                      | Any CVD            | HR = 1.92 (1.33-2.75) | <0.01   |
| Roy                | T1DM             | Prospective      | Moderate DR          | CVD                | OR = 3.19 (1.19-8.57) | 0.01    |
| TARGER             | T2DM             | Prospective      | Severe DR            | CVD                | OR = 3.88 (1.39-10.80)| 0.01    |
| Kawasaki 2013      | T2DM             | Prospective      | DR                   | Incident CVD       | Men: HR = 1.61 (1.20-2.60) All <0.001 |
|                   |                  | (2033)           |                      |                    | Women: HR = 1.67 (1.30-2.80) |
|                   |                  |                  |                      |                    | Men: HR = 3.75 (2.00-7.40) |
|                   |                  |                  |                      |                    | Women: HR = 3.81 (2.20-7.30) |
| Park               | T2DM             | Prospective      | DR                   | CHD                | OR = 2.39 (1.63-3.51) | <0.001  |
| Torffvit           | T1DM             | Prospective      | STDR                 | CVD                | RR = 4.40 (NR) | <0.05   |
| Cheung             | T2DM             | Prospective      | Any DR               | Incident CHD       | HR = 1.99 (1.33-3.00) | NR      |
|                   |                  | (1524)           | Any DR               |                    | HR = 1.91 (1.18-3.08) | NR      |
|                   |                  |                  | Mild/moderate DR     |                    | HR = 1.89 (1.22-2.92) | NR      |
|                   |                  |                  | Severe DR            |                    | HR = 2.57 (1.25-5.27) | NR      |
|                   |                  |                  |                      |                    | HR = 5.38 (1.54-18.82) | NR      |
| Gerstein           | T2DM             | Prospective      | Change in retinal severity | ACCORD composite | HR per category change: 1.38 (1.10-1.74) | <0.05   |
| Rajala             | T1DM & T2DM      | Prospective      | DR                   | CVD mortality      | OR = 5.6 (2.6-19.0) | <0.05   |
| Juutilainen        | T2DM             | Prospective      | Background DR        | CVD mortality      | HR = 1.52 (1.15-1.99) | 0.003   |
|                   |                  | (824)            |                      |                    | HR = 1.47 (1.06-2.02) | 0.020   |
|                   |                  |                  |                      |                    | HR = 3.43 (2.01-5.85) | <0.001  |
|                   |                  |                  |                      |                    | HR = 3.45 (1.87-6.36) | <0.001  |
| Kramer 2011        | T1DM & T2DM      | Meta-analysis    | DR                   | All-cause mortality| T1DM: OR = 3.65 (1.05-12.66) NR |
|                   |                  | (19234)          |                      |                    | T2DM: OR = 2.41 (1.87-3.10) | NR      |

Abbreviations: ABI, ankle-brachial index; β, β coefficient; CI, confidence interval; cIMT, carotid intima-media thickness; CAC, coronary artery calcium; CHD, coronary heart disease; CVD, cardiovascular disease; DR, diabetic retinopathy; HR, hazard ratio; ICA-IMT, internal carotid artery intima-media thickness; NPDR, non-proliferative diabetic retinopathy; NR, not reported; OR, odds ratio; PDR, proliferative diabetic retinopathy; RR, relative risk; STDR, sight-threatening diabetic retinopathy (defined as clinically significant macular oedema and/or severe non-proliferative DR, or clinically significant macular oedema and/or PDR); T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; VTDR, vision-threatening diabetic retinopathy (defined as clinically significant macular oedema or PDR).
Overall, the above findings are consistent with those from other prospective studies, indicating that DR, particularly advanced DR, is an independent risk factor for CVD in patients with diabetes.65,70–72 Furthermore, Torffvit et al. demonstrated that the presence of VTDR in patients with T1DM increases the risk of incident CHD by 4.4 times, compared with no DR presence.73 Notably, the association did not remain after adjusting for the presence of macroalbuminuria.73 However, this contrasts with results from the Atherosclerosis Risk in Communities (ARIC) Study in T2DM, in which adjusting for nephropathy had minimal impact on the association between DR and CHD.96 In this study, the risk of incident CHD increased with DR severity, and severe DR was also a significant independent risk factor for fatal CHD.96

In the ACCORD Eye Study, DR severity and progression were associated with the composite outcome of first occurrence of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death in patients with T2DM.18 Analyses revealed that the risk of this primary outcome increased by 38% for every category of change in DR severity.18 Elsewhere, retinopathy and PDR have been shown to increase the risk of cardiovascular or all-cause mortality in patients with T1DM and patients with T2DM.74–76

### 4.3.3 | Peripheral complications

Neuropathic and vascular complications caused by diabetes can lead to the development of diabetic foot ulcers and infections, and cause amputations. Several studies have shown that DR is an independent risk factor for foot ulceration in individuals with diabetes.77–80 However, a retrospective analysis of patients with T2DM by Tomita et al. found retinopathy to significantly increase the risk of developing ulcers only in the presence of microalbuminuria after adjusting for neuropathy and macroangiopathy.81 Furthermore, it has been shown that, among individuals with newly diagnosed NPDR, those with non-healing foot ulcers have an increased risk of progressing to...
PDR. 82 A number of papers have also identified DR as a key risk factor for lower extremity amputation in both patients with T1DM and patients with T2DM.79,83–87

Notably, patients who have T2DM and undergo lower extremity amputation (LEAs) have been found to be at higher risk of developing DR than those without LEAs.88 This was also observed in the ADVANCE-ON post-trial observational study in T2DM, which demonstrated that lower extremity ulceration or amputation, as a major presentation of PAD, increased the risk of retinal photocoagulation or blindness.89 PAD is diagnosed using the ABI, with values less than 0.9 indicative of the disease.90 Chen et al. demonstrated that DR was independently associated with a low ABI in patients with T2DM, irrespective of age.90 However, Chen et al. found PDR, but not NPDR, to be correlated with an abnormal ABI in patients with T2DM after adjustment for HbA1c.91 This result was replicated in another study, in which PDR was found to be independently associated with other measures of PAD, such as the toe-brachial index, Doppler ultrasound and critical limb ischaemia.92 In addition, a prospective study in African-Americans with T1DM found that DR severity at baseline was a significant independent risk factor for the incidence of lower extremity arterial disease, defined as present if a patient has had an amputation or angioplasty for poor circulation, or if there is an absence of major arterial pulse in the legs.93 However, in patients with T2DM, a borderline ABI (0.90-0.99) has been identified as an independent predictor of DR and other microvascular and macrovascular complications.94

4 | DISCUSSION

The present structured analysis has provided clear evidence supporting relationships between DR and complications of diabetes, including micro- and macrovascular conditions and events. Although many of these associations have been identified in cross-sectional and retrospective studies, several have been confirmed in prospective investigations, based on multivariate analyses that controlled for the influence of traditional or other known risk factors.

With regard to microvascular outcomes, DR was found to increase the likelihood of nephropathy,15,25,26 and to be a significant and independent predictor of progression to micro- or macroalbuminuria,15 but it remains unclear whether albuminuria increases the risk of retinopathy.29,30,37 In this regard, Kotliarsky et al. concluded that renal injury precedes retinal damage, but they stated that prospective studies are required to confirm this conclusion.37 Additionally, the reviewed evidence indicates that DR correlates with declining GFR24,48 and, specifically, that retinopathy severity at baseline is a predictor of the rate of decline of eGFR.48 An important implication of the above findings is that close monitoring of individuals with DR for the presence of other microvascular complications, particularly albuminuria and impaired glomerular function, may help prevent progression to more serious kidney disease.24,95 Furthermore, as evidence suggests that DR severity paralyses the severity of nephropathy, a key area of further research is whether systemic interventions to prevent the progression of one might influence the progression of the other. A strong association was also observed between DR and CAN, with prospective studies indicating that the risk of developing the latter increases in the presence of retinopathy and that, in individuals with T2DM, DR stage is independently correlated with CAN.16,45 As both CAN and DR have been identified as predictors of cardiovascular morbidity and mortality in several prospective studies of individuals with diabetes,65,70–72,96 it may be interesting to investigate whether both conditions in conjunction are associated with a greater risk of cardiovascular complications, compared with the presence of either complication alone. If this were the case, screening for CAN in patients who have diabetes with DR could help identify high-risk groups, for monitoring and early detection of clinical progression to CVD. Outcomes from the reviewed studies also demonstrate that DR is a significant risk factor for DPN,38,40,41,51 and that the risk of developing this complication is greater in the presence of PDR than with early-stage retinopathy.41

As for the relationship between DR and the macrovascular complications of diabetes, risk estimates from several large prospective studies indicate that DR is a strong predictor of stroke, and that progression of DR significantly increases the risk of this complication.22,52,53 Severe DR was found to independently increase the risk of cerebral infarction and cerebral haemorrhage in patients with T1DM,22 and was associated with small-artery ischaemic stroke in patients with T2DM.23 Evidence presented here also demonstrates that DR is associated with subclinical atherosclerosis,51–53 and that the presence of this complication is independently correlated with CIMT and carotid plaques in T2DM populations.17,61,65 Two studies showed that DR is associated with increased risk of CHD-related events and mortality53,55 and, overall, DR was found to be an independent risk factor for CVD.65,70–72 Similarly, outcomes from the reviewed studies demonstrate that DR, and particularly PDR, is a strong risk factor for PAD, which carries a risk of lower extremity ulceration and amputation.90–92 Therefore, worsening DR could prove useful as a marker for individuals at increased risk of these serious macrovascular complications. Specifically, the evidence indicates that patients with diabetes who have PDR are more likely than those with NPDR to have an abnormal ABI.91 Furthermore, DR was identified as an independent risk factor for foot ulceration and a key risk factor for lower extremity amputation.77–79 Interestingly, two studies found that patients with diabetes who have non-healing foot ulcers or who have undergone lower extremity amputation are at risk of DR development and progression.82,88

We performed a comprehensive search of the literature that resulted in the inclusion of 71 studies, with a total of over 400 000 patients, and the approach taken to review was objective and systematic, complying with several of the key items included in the PRISMA checklist for systematic reviews and meta-analyses. One limitation of our study was that only the PubMed literature database was searched. Despite this, our findings are an important contribution to the understanding of the relationship between DR and the micro- and macrovascular complications of diabetes and, as such, provide valuable information to support the wider multidisciplinary team that is involved in the care of individuals with diabetes. In particular, the findings underscore the need for prompt screening and referral for DR, which can both reduce vision loss and, potentially, identify patients at increased risk of other complications of diabetes. This highlights the
need for a coordinated and collaborative approach to patient management on the part of all the healthcare professionals involved in diabetes care in order to optimize clinical outcomes. A risk assessment model that incorporates DR presence as an input factor, rather than an outcome, may provide a powerful tool for identifying individuals at high risk of potentially life-threatening complications of diabetes. Indeed, a study has demonstrated that incorporation of microvascular complications into cardiovascular risk algorithms improves CVD risk prediction in T2DM.100 The ability to identify the individuals most at risk of developing complications could improve the targeting of preventive treatments, potentially reducing morbidity and mortality among patients with diabetes. Further exploration in this area is warranted.

ACKNOWLEDGMENTS

Medical writing assistance was provided by Lorena Tonarelli, MSc and Lisa Gallacher, PhD of Porterhouse Medical, and was funded by Bayer. The authors acknowledge the contribution of Professor Paul Dodson in the conception of this review and manuscript.

CONFLICT OF INTEREST

M. E. has nothing to disclose. I. P. reports consulting fees/lectureship fees from Bayer and Novartis, and consulting fees from Allergan, outside the submitted work. R. S. has nothing to disclose. M. L.-A. has nothing to disclose. D. T. W. reports educational grants and personal fees from Bayer, Valeant and Novartis, and personal fees from Allergan, outside the submitted work. Potential conflicts that the authors consider relevant to the content of the manuscript have been disclosed.

Author contributions

All authors contributed to the concept development, determining the search strategy and evaluating the results for inclusion, and provided critical review of the manuscript.

ORCID

Rafael Simó https://orcid.org/0000-0003-0475-3096
Marc Evans https://orcid.org/0000-0003-0671-0778

REFERENCES

1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-564.
2. Jee D, Lee WK, Kang S. Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008-2011. Invest Ophthalmol Vis Sci. 2013;54:6827-6833.
3. Simó R, Hernández C. European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014;25:23-33.
4. Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:412-418.
5. Hames HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes. 2011;60:9-16.
6. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; 2015. http://www.diabetesatlas.org. Accessed February 13, 2018.
7. Flaxman SR, Bourne RR, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221-e1234.
8. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60:428-431.
9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
10. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
11. Korobelnik J-F, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247-2254.
12. Scanlon PH, Aldington SJ, Stratton IM. Delay in diabetic retinopathy screening increases the rate of detection of referable diabetic retinopathy. Diabet Med. 2014;31:439-442.
13. Villar G, Garcia Y, Goicolea I, Vázquez JA. Determinants of development of microalbuminuria in normotensive patients with type 1 and type 2 diabetes. Diabetes Metab. 1999;25:246-254.
14. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Moharram OA, Kangave D. Retinopathy as a predictor of other diabetic complications. Int Ophthalmol. 2001;24:1-11.
15. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care. 2002;25:859-864.
16. Huang CC, Lee JJ, Lin TK, et al. Diabetic retinopathy is strongly predictive of cardiovascular autonomic neuropathy in type 2 diabetes. J Diabetes Res. 2016;2016:6090749.
17. Alonso N, Travaset A, Rubinat E, et al. Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy. Cardiovasc Diabetol. 2015;14:33.
18. Gerstein HC, Ambrosius WT, Danis R, et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care. 2013;36:1266-1271.
19. Zhu XR, Zhang YP, Bai L, Zhang XL, Zhou JB, Yang JK. Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure: evidence from epidemiological observational studies. Medicine (Baltimore). 2017;96:e5894.
20. Gomez CR. Carotid plaque morphology and risk for stroke. Stroke. 1990;21:148-151.
21. Hägg S, Thorn LM, Forsblom CM, et al. Different risk factor profiles for ischemic and hemorrhagic stroke in type 1 diabetes mellitus. Stroke. 2014;45:2558-2562.
22. Hägg S, Thorn LM, Putaat J, et al. Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care. 2013;36:4140-4146.
23. Hankey GJ, Anderson NE, Ting RD, et al. Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study. J Neurol Neurosurg Psychiatry. 2013;84:281-287.
24. ICO Guidelines for Diabetic Eye Care. https://www.bing.com/search?q=ico+guidelines+for+diabetic+eye+care&form=EDGEAR&qs=AS&cvid=2f8ec386b2314450af54f0380d1f3af8a&cc=US&setlang=en-US&PC=DCTS. Accessed October 16, 2018.
25. Parving HH, Lewis JB, Ravid M, Remuzzi G, Huniscker LG, DEMAND Investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69:2057-2063.
26. Karlberg C, Falk C, Green A, Sjellie AK, Grauslund J. Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients. Acta Diabetol. 2012;49:263-268.
27. Kramer CK, Retnakaran R. Concordance of retinopathy and nephropathy over time in type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabet Med. 2013;30:1333-1341.
28. Romero-Aroca P, Baget-Bernaldiz M, Reyes-Torres J, et al. Relationship between diabetic retinopathy, microalbuminuria and overt nephropathy, and twenty-year incidence follow-up of a sample of type 1 diabetic patients. J Diabetes Complications. 2012;26:506-512.

29. Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, et al. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Res Clin Pract. 2011;94:126-132.

30. Hammes HP, Welp R, Kempe HP, et al. Risk factors for retinopathy and DME in type 2 diabetes—results from the German/Austrian DPV Database. PLoS One. 2015;10:e0132492.

31. Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang U. Diabetic retinopathy in patients with diabetic nephropathy: development and progression. PLoS One. 2016;11:e0161897.

32. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, nephropathy, and cardiovascular disease in NIDDM. Diabetes Care. 1996;19:1243-1248.

33. Takagi M, Babazono T, Uchigata Y. Differences in risk factors for the onset of albuminuria and decrease in glomerular filtration rate in people with type 2 diabetes mellitus: implications for the pathogenesis of diabetic kidney disease. Diabet Med. 2015;32:1354-1360.

34. Moriya T, Tanaka S, Kawasaki R, et al. Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study. Diabetes Care. 2013;36:2803-2809.

35. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164-176.

36. Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: the FIND-眼study. Invest Ophthalmol Vis Sci. 2008;49:3839-3845.

37. Kotlarsky P, Bolotin A, Dorfman K, Knyazer B, Lifshitz T, Levy J. Link between retinopathy and nephropathy caused by complications of diabetes mellitus type 2. Int Ophthalmol. 2015;35:59-66.

38. Kostev K, Jockwig A, Hallwachs A, Rathmann W. Prevalence and risk factors of nephropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and U.K. Prim Care Diabetes. 2014;8:250-255.

39. Jurado J, Ybarra J, Romeo JH, Pou JM. Clinical screening and diagnosis of diabetic polyneuropathy: the North Catalonia Diabetes Study. Eur J Clin Invest. 2009;39:183-189.

40. Abougalambou SS, Abougalambou AS. Risk factors associated with diabetic retinopathy among type 2 diabetes patients at teaching hospital in Malaysia. Diabetes Metab Syndr. 2015;9:98-103.

41. Lin IC, Wang YH, Lin CL, Chang YJ, Lee SH, Wang UJ. Diabetic polyneuropathy and the risk of developing diabetic retinopathy: a nationwide, population-based study. Acta Ophthalmol. 2015;93:713-718.

42. Zander E, Herfurth S, Bohl B, et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol. 2000;84:871-876.

43. Witte DR, Tesfaye S, Chaturvedi N, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48:164-171.

44. Ko SH, Song KH, Park SA, et al. Cardiovascular autonomic dysfunction predicts acute ischaemic stroke in patients with type 2 diabetes mellitus: a 7-year follow-up study. Diabet Med. 2008;25:1171-1177.

45. Vouglari C, Psallas M, Kokkinos A, Argiria V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. 2011;25:159-167.

46. Chen HT, Lin HD, Won JG, et al. Cardiovascular autonomic neuropathy, autonomic symptoms and diabetic complications in 674 type 2 diabetes. Diabetes Res Clin Pract. 2008;82:282-290.

47. Gaspar L, Kruzlak P, Komornikova A, et al. Orthostatic hypotension in diabetic patients—10-year follow-up study. J Diabetes Complications. 2016;30:67-71.

48. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596-1605.

49. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic nephropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521-534.

50. Fisher VL, Tahranii AA. Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes Metab Syndr Obes. 2017;10:419-434.

51. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ III, O’Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care. 1999;22:1479-1486.

52. Pettiti DB, Bhatt H. Retinopathy as a risk factor for nonembolic stroke in diabetic subjects. Stroke. 1995;26:593-596.

53. Cheung N, Rogers S, Couper DJ, Klein R, Sharrett AR, Wong TY. Is diabetic retinopathy an independent risk factor for ischemic stroke? Stroke. 2007;38:398-401.

54. Klein BE, Klein R, McBride PE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 2004;164:1917-1924.

55. Kawasaki R, Tanaka S, Tanaka S, et al. Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. Ophthalmology. 2013;120:574-582.

56. Cheung N, Mosley T, Islam A, et al. Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain. 2010;133:1967-1993.

57. Lip GYH, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2015;147:1103-1110.

58. Chou AY, Liu CJ, Chao TF, et al. Presence of diabetic microvascular complications does not incrementally increase risk of ischemic stroke in diabetic patients with atrial fibrillation: a nationwide cohort study. Medicine (Baltimore). 2016;95:e9392.

59. Bartels S, Ruiz Franco A, Rundek T. Carotid intima-media thickness (cIMT) and plaque from risk assessment and clinical use to genetic discoveries. Perspect Med. 2012;1:139-145.

60. Klein R, Sharrett AR, Klein BE, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology. 2002;109:1225-1234.

61. Rema M, Mohan V, Deepa R, Ravikumar R, Chennai Urban Rural Epidemiology Study-2. Rural Epidemiology Study-2. Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes Care. 2004;27:1962-1967.

62. Liu Y, Teng X, Zhang W, Zhang R, Liu W. Association between diabetic retinopathy and subclinical atherosclerosis in China: results from a community-based study. Diab Vasc Dis Res. 2015;12:366-372.

63. Saif A, Karawya S, Abdelhamid A. Retinopathy is a strong determinant of atherosclerosis in type 2 diabetes: correlation with carotid intima media thickness. Endocr Pract. 2015;21:226-230.

64. Son JW, Jang EH, Kim MK, et al. Diabetic retinopathy is associated with subclinical atherosclerosis in newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;91:253-259.

65. Park GM, Lee SW, Cho YR, et al. Diabetic retinopathy is associated with carotid atherosclerosis in newly diagnosed type 2 diabetes mellitus: Am J Cardiol. 2014;113:765-771.

66. Li LX, Li MF, Lu JX, et al. Retinal microvascular abnormalities are associated with early carotid atherosclerotic lesions in hospitalized Chinese patients with type 2 diabetes mellitus. J Diabetes Complications. 2014;28:378-385.

67. de Kreutzgenberg SV, Coracina A, Volpi A, et al. Microangiopathy is independently associated with presence, severity and composition of carotid atherosclerosis in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21:286-293.

68. Kawasaki R, Cheung N, Islam FM, et al. Is diabetic retinopathy related to subclinical cardiovascular disease? Ophthalmology. 2011;118:860-865.

69. Reaven PD, Emanuele N, Moritz T, et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in
the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2008;31: 952-957.

70. Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2009;103:1364-1367.

71. Roy MS, Peng B, Roy A. Risk factors for coronary disease and stroke in previously hospitalized African-Americans with type 1 diabetes: a 6-year follow-up. Diabet Med. 2007;24:1361-1368.

72. Targher G, Bertolini L, Zenari L, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet Med. 2008;25:45-50.

73. Torffvit O, Lövestam-Adrian M, Agardh E, Agardh CD. Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes: a 12-year observation study of 462 patients. Diabet Med. 2005;22:723-729.

74. Rajala U, Pajunpää H, Koskela P, Keinänen-Kiukaanniemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care. 2000;23: 957-961.

75. Juutilainen A, Lehto S, Rönnema T, Pyörälä K, Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care. 2007;30:292-299.

76. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care. 2011;34:1238-1244.

77. Baba M, Davis WA, Davis TM. A longitudinal study of foot ulceration and its risk factors in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2014;106:42-49.

78. Leymarie F, Richard JL, Malgrange D. Factors associated with diabetic patients at high risk for foot ulceration. Diabetes Metab. 2005; 31:603-605.

79. Bruun C, Siersma V, Guassora AD, Holstein P, de Fine Olivarius N. Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity. Diabet Med. 2013;30:964-972.

80. Parisi MC, Moura Neto A, Menezes FH, et al. Baseline characteristics and risk factors for ulcer, amputation and severe neuropathy in diabetic foot at risk: the BRAZUPA study. Diabetol Metab Syndr. 2016;8:25.

81. Tomita M, Kabeya Y, Okisugi M, et al. Diabetic microangiopathy is an independent predictor of incident diabetic foot ulcer. J Diabetes Res. 2016;2016:9538540.

82. Harris Nwanyanwu K, Talwar N, Gardner TW, Wrobel JS, Herman WH, Stein JD. Predicting development of proliferative diabetic retinopathy. Diabetes Care. 2013;36:1562-1568.

83. Chaturvedi N, Stevens LK, Fuller JH, Lee ET, Lu M. Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):S56-S57.

84. Hämmäläinen H, Rönnemaa T, Halonen JP, Toikka T. Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: a population-based 7-year follow-up study. J Intern Med. 1999;246:97-103.

85. Lai YJ, Hu HY, Lin CH, Lee ST, Kuo SC, Chou P. Incidence and risk factors of lower extremity amputations in people with type 2 diabetes in Taiwan, 2001-2010. J Diabetes. 2015;7:260-267.

86. Rodrigues BT, Vangaveti VN, Malabu UH. Prevalence and risk factors for diabetic lower limb amputation: a clinic-based case control study. J Diabetes Res. 2016;2016:9541957.

87. Saltoglu N, Yemisen M, Ergonul O, et al. Predictors for limb loss among patient with diabetic foot infections: an observational retrospective multicentric study in Turkey. Clin Microbiol Infect. 2015;21: 659-664.

88. Tsai FC, Lan YC, Muo CH, et al. Subsequent ischemic events associated with lower extremity amputations in patients with type 2 diabetes: a population-based cohort study. Diabetes Res Clin Pract. 2015; 107:85-93.

89. Mohammadi K, Woodward M, Hirakawa Y, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol. 2016;15:129.

90. Li X, Wang YZ, Yang XP, Xu ZR. Prevalence of and risk factors for abnormal ankle-brachial index in patients with type 2 diabetes. J Diabetes. 2012;4:140-146.

91. Chen SC, Hisiao PJ, Huang JC, et al. Abnormally low or high ankle-brachial index is associated with proliferative diabetic retinopathy in type 2 diabetic mellitus patients. PLoS One. 2015;10:e0134718.

92. Chen YW, Wang YY, Zhao D, et al. High prevalence of lower extremity peripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy. PLoS One. 2015;10:e0122022.

93. Roy MS, Peng B. Six-year incidence of lower extremity arterial disease and associated risk factors in type 1 diabetic African-Americans. Diabet Med. 2008;25:550-556.

94. Yan BP, Zhang Y, Kong AP, et al. Borderline ankle-brachial index is associated with increased prevalence of micro- and macrovascular complications in type 2 diabetes: a cross-sectional analysis of 12,772 patients from the Joint Asia Diabetes Evaluation Program. Diab Vasc Dis Res. 2015;12:334-341.

95. Hernández C, Candell-Riera J, Ciudin A, Francisco G, Aguadé-Bruix S, Simó R. Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects. Cardiovasc Diabetol. 2011:109.

96. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007;30: 1742-1746.

97. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes—A review. Diabet Med. 2010;27:4-14.

98. Sabanayagam C, Foo VH, Ikrar MK, et al. Is chronic kidney disease associated with diabetic retinopathy in Asian adults? J Diabetes. 2014;6:556-563.

99. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:334-339.

100. Brownrigg JR, Hughes CO, Burleigh D, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 2016;4:588-597.

How to cite this article: Pearce I, Simó R, Lövestam-Adrian M, Wong DT, Evans M. Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes Obes Metab. 2019;21:467-478. https://doi.org/10.1111/dom.13550